Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$8.1B
152M shares
52-week range
$30.09 – $65.30
64% from low
Sector
LABORATORY ANALYTICAL INSTRUMENTS
Exchange
NASDAQ
CS
P/S (TTM)
2.3
EV / FCF (TTM)
104
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST) . The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
www.bruker.comNo one on the platform currently holds BRKR.
| Institution | Shares | Reported |
|---|---|---|
| Scion Asset Managementas of 2025-06-30 | 250,000 | $10.3M |
| Renaissance Technologiesas of 2025-09-30 | 139,610 | $4.5M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-09-21 | $0.0500 | 2026-10-07 |
| 2026-06-22 | $0.0500 | 2026-07-07 |
| 2026-03-23 | $0.0500 | 2026-04-07 |
| 2025-12-08 | $0.0500 | 2026-01-02 |
| 2025-09-23 | $0.0500 | 2025-10-03 |
| 2025-06-16 | $0.0500 | 2025-06-27 |
| 2025-03-17 | $0.0500 | 2025-03-28 |
| 2024-12-02 | $0.0500 | 2024-12-16 |
| 2024-08-30 | $0.0500 | 2024-09-16 |
| 2024-06-03 | $0.0500 | 2024-06-17 |
No one on the platform has traded BRKR yet.
| 2024-02-29 | $0.0500 | 2024-03-15 |
| 2023-11-30 | $0.0500 | 2023-12-15 |
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | -2.3% | 11.1% | 14.1% | — | — | — |
| Rev. Growth % | 2.1% | 11.6% | ||||
| Profit Margin % | -0.3% | 8.1% | 8.2% | |||
| Free Cash Flow Margin % | 0.4% | 5.3% | 6.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +5.3% on the P/E track.
At today's price, your expected annual return is +10.5% on the P/E track.
At today's price, your expected annual return is +14.8% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $3.6B | +3.9% | $2.12 | $2.11–$2.16 | 24.8× | 7 |
| 2027 | $3.7B | +4.1% | $2.40 | $2.32–$2.49 | 22.0× | 7 |
| 2028 | $3.9B | +5.7% | $2.79 | $2.54–$3.03 | 18.9× | 2 |
| 2029 | $4.2B | +8.1% | $3.27 | $3.23–$3.32 | 16.1× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-04 | $0.38 | $0.49 | +27.3% |
| 2026-05-06 | $0.23 | $0.31 | +34.8% |
| 2026-02-12 | $0.65 | $0.59 | -9.2% |
| 2025-11-03 | $0.33 | $0.60 | +81.8% |
| 2025-08-04 | $0.33 | $0.32 | -3.0% |
| 2025-05-07 | $0.46 | $0.47 | +2.2% |
| 2025-02-13 | $0.75 | $0.76 | +1.3% |
| 2024-11-05 | $0.61 |
| $0.60 |
| -1.6% |
| $10.1B |
| — |
| IRTCiRhythm Technologies, Inc. | $114.72 | +2.95% | $3.8B | — |
| KRYSKrystal Biotech, Inc. | $340.03 | -2.01% | $10.0B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$BRKR What is Jack "Mr AXDX Bankruptcy" doing on this company's Board of Directors?
View on StockTwits ↗
@ChineseTakeeout bulls can expect to wait. there was no expectation turnaround would happen fast, so stock surely prices in that vague future by now, one would think? and the transition probably happened slower because science got attacked by its own government for a year straight. $BRKR reporting great numbers because of AI/energy demand could be a sign of things to come, but the "trickle down" from non-bio to bio doesn't directly route through Ginkgo as cleanly. it's more indirect, but i think larger possible market if/when gears get turning. similar biotech tide turning evidence from $TWST. and $ARKG is in fire too, outpacing XBI now IIRC. DNA won't ride that wave until dreams stop being memes and start being dollars, but the outlook is better than the strong previous years' (decades') headwinds. and more national lab / defense / academia partnerships are great seeds to plant (but long-term and won'tt be a sole driver). it's all a big, incredibly cool, science-y TBD! 🧬🫶 people should absolutely be aware they're investing in a vision for the future here. the future Ginkgo expects is all but inevitable, but it's up to Ginkgo to execute still. and hopefully they can, to accelerate the rate of the autonomous US lab buildout along the way and prevent another offshoring catastrophe.
View on StockTwits ↗
https://www.marketbeat.com/earnings/reports/2026-8-4-bruker-co-stock/ $BRKR Bruker Earnings Transcript
View on StockTwits ↗
$BRKR Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.41 down -920.00% YoY • Reported revenue of $838.5M up 5.15% YoY • Bruker Corporation updates its fiscal year 2026 revenue guidance to $3.54 to $3.57 billion, reflecting 3% to 4% year-over-year growth, and maintains non-GAAP EPS guidance of $2.10 to $2.15 per share.
View on StockTwits ↗
$BRKR Chart made with @TrendSpider https://share.trendspider.com/chart/BRKR/7594xszz8b
View on StockTwits ↗$BRKR shaping a new base after first rally...fresh momentum.
View on StockTwits ↗
$BRKR amazing tight flag here
View on StockTwits ↗
Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.